Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PF-07328948
Low Dose PF-07328948 · 1 trial · 1 indication
Adjudicated cardiovascular death and worsening heart failure events through 36 weeks.
A submaximal exercise test that measures the distance the participant can walk within prescribed time of 6 minutes. Participants are asked to perform the test at a pace comfortable to them with as many breaks as needed. The total distance walked is recorded.
KCCQ is a 23-item heart-failure specific questionnaire quantified into the following scores: symptom frequency, symptom burden, symptom stability, physical limitations, social limitations, quality of life, and self-efficacy, total symptom score, overall summary score, and clinical summary score. To facilitate interpretation, all scores are presented on a scale of 0 to 100 points, with lower scores indicating more severe symptoms and/or limitations, and a score of 100 indicating no symptoms, no limitations, and excellent quality of life.
| Arm | Type | Description |
|---|---|---|
| ARM 1 | PLACEBO_COMPARATOR | Placebo Participants will receive Placebo for up to 36 weeks |
| ARM 2 | EXPERIMENTAL | Low dose PF-07328948 Participants will receive PF-07328948 for up to 36 weeks |
| ARM 3 | EXPERIMENTAL | Medium dose PF-07328948 Participants will receive PF-07328948 for up to 36 weeks |
| ARM 4 | EXPERIMENTAL | High dose PF-07328948 Participants will receive PF-07328948 for up to 36 weeks |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | ARM 1 |
| Low Dose PF-07328948 | DRUG | ARM 2 |
| Medium Dose PF-07328948 | DRUG | ARM 3 |
| High Dose PF-07328948 | DRUG | ARM 4 |
This study is seeking participants who are: Key Inclusion Criteria include: * aged 18 years to \< 80 years * clinically confirmed to have a diagnosis of heart failure for at least 3 months * New York Heart Association Class II-IV symptoms * left ventricular ejection fraction greater than 40% * Kan...
Top 20 of 31 competitors
Low Dose PF-07328948 is an investigational small molecule being developed by Pfizer for cardiovascular conditions, specifically heart failure. It is currently in Phase 2 clinical trials for heart failure, with additional Phase 1 studies in healthy adults and in people with hepatic or renal impairment.
Low Dose PF-07328948 is being developed by Pfizer, Inc., which trades under the ticker symbol PFE on the New York Stock Exchange. The company is conducting multiple clinical trials to evaluate the drug in various populations, including healthy adults and patients with heart failure.
Low Dose PF-07328948 is in Phase 2 clinical development for heart failure, as shown by the recruiting BRANCH-HF trial. It is also being studied in Phase 1 trials for hepatic and renal impairment. The drug is investigational and has not been approved by regulatory authorities.
Low Dose PF-07328948 is being studied in several trials. NCT06991257 is a Phase 2 study in adults with heart failure. NCT06837259 is a completed Phase 1 drug interaction study in healthy adults. NCT07269301 and NCT07315360 are Phase 1 studies in hepatic and renal impairment, respectively.
Yes, Low Dose PF-07328948 is the same as PF-07328948. The drug is referred to by both names in clinical trial records, with PF-07328948 being the primary identifier used in study titles and descriptions.
Low Dose PF-07328948 is not FDA approved. It is an investigational drug currently in Phase 2 clinical trials for heart failure and Phase 1 trials for other conditions. Approval status has not been granted, and the drug remains in clinical development.